Cendakimab Shows Promise in Phase II Trial for Atopic Dermatitis
July 17, 2024
-
3 min
5 Key Takeaways
-
1
Cendakimab, an anti–interleukin-13 monoclonal antibody, was investigated in a phase II clinical trial for atopic dermatitis.
-
2
The study found that the 720 mg once-weekly dose of cendakimab showed the greatest improvement in Eczema Area and Severity Index (EASI) scores compared to placebo.
-
3
Adverse events, including conjunctivitis, were generally mild to moderate.
-
4
The results suggest that cendakimab may be a safe and effective treatment for atopic dermatitis.
-
5
Larger trials are warranted to further investigate cendakimab's role in treating atopic dermatitis.
A phase II clinical trial investigated cendakimab, an anti–interleukin-13 monoclonal antibody, and its potential to improve symptoms in adult patients with moderate to severe atopic dermatitis. The study demonstrated that cendakimab significantly reduced Eczema Area and Severity Index (EASI) scores compared to placebo, with the 720 mg once-weekly dose showing the greatest improvement. Adverse events were generally mild to moderate, with higher rates of conjunctivitis in the cendakimab groups. The findings suggest that cendakimab could be a safe and effective treatment for atopic dermatitis, supporting further investigation in larger trials.
Listen Tab content
